Volume 28, Number 11—November 2022
Dispatch
Effect of COVID-19 Pandemic on Invasive Pneumococcal Disease in Children, Catalonia, Spain
Table 2
Healthcare activity and IPD incidence by quarter, Catalonia, Spain, 2018–19 and 2020*
Variable | No. cases (incidence, cases/100,000 population) |
IRR (95% CI) | p value | |
---|---|---|---|---|
Mean 2018–2019 | 2020 | |||
1st quarter | ||||
Emergency department visits | 61,590 (11,838.5) | 54,430 (10,413.7) | 0.88 (0.87–0.89) | <0.0001 |
Hospital admissions | 3,049 (586.1) | 2,785 (532.8) | 0.91 (0.86–0.96) | 0.0003 |
Samples for culture, HSJD | 1,968 (378.3) | 2,192 (419.4) | 1.11 (1.04–1.18) | 0.0009 |
Samples for PCR, HSJD and VH | 185 (35.6) | 182 (34.8) | 0.98 (0.80–1.20) | 0.84 |
IPD cases | 17 (3.3) | 15 (2.9) | 0.88 (0.43–1.77) | 0.72 |
PCV13 serotypes | 7 (1.3) | 9 (1.7) | 1.28 (0.47–3.62) | 0.64 |
Serotype 3 | 5 (1.0) | 8 (1.5) | 1.59 (0.51–5.35) | 0.43 |
Non-PCV13 serotypes |
10 (1.9) |
6 (1.1) |
0.60 (0.20–1.65) |
0.33 |
2nd quarter | ||||
Emergency department visits | 55,519 (10,671.6) | 23,025 (4,405.2) | 0.41 (0.40–0.42) | <0.0001 |
Hospital admissions | 2,772 (532.8) | 1,670 (319.5) | 0.60 (0.56–0.64) | <0.0001 |
Samples for culture, HSJD | 1,891 (363.5) | 1,633 (312.4) | 0.86 (0.80–0.92) | <0.0001 |
Samples for PCR, HSJD and VH | 141 (27.1) | 107 (20.5) | 0.76 (0.59–0.97) | 0.03 |
IPD cases | 15 (2.9) | 0 | NA | <0.0001 |
PCV13 serotypes | 8 (1.5) | 0 | NA | 0.008 |
Serotype 3 | 6 (1.2) | 0 | NA | 0.03 |
Non-PCV13 serotypes |
6 (1.2) |
0 |
NA |
0.03 |
3rd quarter | ||||
Emergency department visits | 44,594 (8,571.6) | 34,933 (6,683.5) | 0.78 (0.77–0.79) | <0.0001 |
Hospital admissions | 2,171 (417.3) | 1,810 (346.3) | 0.83 (0.78–0.88) | <0.0001 |
Samples for culture, HSJD | 1,789 (343.9) | 1,618 (309.6) | 0.90 (0.84–0.96) | 0.002 |
Samples for PCR, HSJD and VH | 112 (21.5) | 86 (16.5) | 0.76 (0.58–1.01) | 0.06 |
IPD cases | 6 (1.2) | 2 (0.4) | 0.33 (0.05–1.57) | 0.18 |
PCV13 serotypes | 2 (0.4) | 0 | – | 0.25 |
Serotype 3 | 1 (0.2) | 0 | – | 0.50 |
Non-PCV13 serotypes |
3 (0.6) |
2 (0.4) |
0.66 (0.11–3.97) |
0.65 |
4th quarter | ||||
Emergency department visits | 65,445 (12,579.5) | 36,249 (6,935.3) | 0.55 (0.54–0.56) | <0.0001 |
Hospital admissions | 3,321 (638.4) | 2,158 (412.9) | 0.65 (0.61–0.68) | <0.0001 |
Samples for culture, HSJD | 1,841 (353.9) | 1,663 (318.2) | 0.90 (0.84–0.96) | 0.002 |
Samples for PCR, HSJD and VH | 203 (39.0) | 122 (23.3) | 0.60 (0.48–0.75) | <0.0001 |
IPD cases | 19 (3.7) | 3 (0.6) | 0.16 (0.04–0.49) | 0.001 |
PCV13 serotypes | 8 (1.5) | 1 (0.2) | 0.12 (0.01–0.78) | 0.02 |
Serotype 3 | 5 (1.0) | 1 (0.2) | 0.20 (0.01–1.44) | 0.22 |
Non-PCV13 serotypes | 10 (1.9) | 2 (0.4) | 0.20 (0.03–0.82) | 0.02 |
*HSJD, Hospital Sant Joan de Dèu; HVH, Hospital Vall Hebron; IPD, invasive pneumococcal disease; IRR, incidence rate ratio; NA, not applicable; PCV13, 13-valent pneumococcal conjugate vaccine.
Page created: September 22, 2022
Page updated: October 24, 2022
Page reviewed: October 24, 2022
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.